RIPK1 — Receptor-Interacting Protein Kinase 1

Overview

RIPK1 (Receptor-Interacting Protein Kinase 1) is a multifunctional serine/threonine kinase encoded on chromosome 6p25.2 that occupies a central regulatory node in cell death and innate immune signaling. RIPK1 serves as a molecular switch controlling three distinct cell fates: NF-κB-mediated survival and inflammation, caspase-8-dependent apoptosis, and MLKL-dependent necroptosis. The kinase domain activity is dispensable for NF-κB activation but is absolutely required for both apoptotic and necroptotic signaling, a distinction that makes RIPK1 an unusually tractable therapeutic target because kinase-dead (D138N) knock-in mice are viable and developmentally normal, whereas null animals die perinatally from multi-organ failure.

RIPK1 contains three major functional domains: an N-terminal kinase domain, a central RHIM (RIP Homotypic Interaction Motif) domain for interaction with RIPK3 and TRIF, and a C-terminal death domain enabling recruitment to TNFR1 and other death-domain-containing receptors.

Mechanism of Action in Neurodegeneration

Upon TNF-α ligation of TNFR1, RIPK1 is recruited into complex I with TRADD, TRAF2/5, and cIAP1/2, where K63-polyubiquitylation drives downstream NF-κB activation. Deubiquitylation of RIPK1 by CYLD or OTULIN, or phosphorylation imbalances, shift RIPK1 into pro-death complexes. Complex IIa pairs RIPK1 with FADD and caspase-8 to drive apoptosis; when caspase-8 is inhibited or absent, RIPK1 autophosphorylates at Ser166 and forms the necrosome with RIPK3. RIPK3 then phosphorylates MLKL, which oligomerizes and translocates to the plasma membrane to execute necroptotic lysis. PMID:31048504

Neurons are especially vulnerable to RIPK1-driven necroptosis because they developmentally downregulate caspase-8 expression, leaving the necroptotic branch as the dominant cell-death output when upstream signals converge. In neurodegeneration, multiple damage-associated signals converge on RIPK1 activation: TNF-α from activated microglia, ZBP1 sensing of cytoplasmic nucleic acids released by damaged mitochondria, and TLR-mediated innate immune signaling all funnel through RIPK1. TBK1—itself a frequent ALS/FTD mutation target—normally phosphorylates RIPK1 at Ser321 to suppress its activation; loss-of-function TBK1 mutations therefore directly unleash RIPK1 kinase activity in motor and cortical neurons. PMID:30146158

In ALS, RIPK1 is transcriptionally and post-translationally activated in spinal motor neurons of SOD1 mutant mice and human ALS patients. Pharmacologic inhibition with Nec-1s (necrostatin-1s), a selective allosteric RIPK1 inhibitor, delayed disease onset, extended survival, and preserved motor neuron numbers in SOD1-G93A mice. Genetic replacement of RIPK1 with the kinase-dead D138N allele produced equivalent protection, demonstrating that kinase activity, not RIPK1 protein scaffolding, drives the pathology. PMID:27493188 Whether the protective effect is mediated primarily through blocking neuronal necroptosis or by suppressing microglial RIPK1-driven neuroinflammation remains an active area of investigation.

Key Experimental Evidence

Mouse models: Constitutive Ripk1 kinase-dead (D138N/D138N) knock-in mice are healthy and fertile, validating the therapeutic strategy of kinase-only inhibition. SOD1-G93A mice treated with Nec-1s from symptom onset showed a ~20% extension in survival and significant preservation of lumbar motor neurons PMID:27493188. Ripk3 deletion in SOD1 mice rescued motor neuron death in primary cultures but failed to extend survival in vivo, suggesting that RIPK1-dependent apoptosis or non-MLKL necroptotic mechanisms operate in parallel PMID:30815534. Conditional neuronal deletion studies have further implicated microglial RIPK1 as a key source of pro-inflammatory cytokines amplifying neurodegeneration.

Human genetics: TBK1 haploinsufficiency causes ALS/FTD and directly increases RIPK1 activation, positioning TBK1-RIPK1 crosstalk as a central ALS pathway PMID:30146158. Human ALS motor cortex shows elevated RIPK1 S166 phosphorylation (the activation mark) compared to controls.

Alzheimer’s disease: Post-mortem AD brains show elevated pRIPK3 and pMLKL in neurons surrounding Aβ plaques, with necroptotic markers correlating with Braak staging and synaptic protein loss. TNF-α, which is markedly elevated in AD cerebrospinal fluid and brain parenchyma, is the canonical activator of RIPK1 in these neurons, creating a feed-forward loop where neuronal death releases DAMPs that further activate microglia PMID:34646380. A 2025 systematic review across human and animal AD studies confirmed necroptotic pathway activation as a consistent feature PMID:41042431.

RIPK1 Checkpoint Regulation and Genetic Architecture

RIPK1 kinase activation is governed by a multi-layered checkpoint system of inhibitory phosphorylations that normally suppress its cytotoxic potential. Upon TNF-stimulation, IKKβ phosphorylates RIPK1 at Ser25 (and Ser321), MK2 phosphorylates Ser321, and TBK1 phosphorylates Ser321 independently — these marks collectively inhibit RIPK1 autophosphorylation at Ser166 and prevent complex II formation. PMID:30146158 This architecture explains why multiple ALS/FTD-associated gene mutations converge on RIPK1 hyperactivation: TBK1 haploinsufficiency directly removes a checkpoint kinase; loss-of-function mutations in CYLD and OTULIN deubiquitylases generate deubiquitylated RIPK1 that is primed for complex IIa assembly; and optineurin (OPTN) loss-of-function disrupts M1-polyubiquitin chains that normally recruit checkpoint kinases to the TNFR1 signaling complex. Thus, the RIPK1 checkpoint can be eroded by any one of several ALS-relevant genetic lesions, collectively shifting the neurodegenerative trajectory toward enhanced RIPK1-driven neuronal death.

Beyond ALS/FTD, post-mortem Parkinson’s disease brain tissue shows elevated phospho-RIPK3 and phospho-MLKL in substantia nigra dopamine neurons and surrounding striatal neurons, indicating that necroptotic signaling is active in synucleinopathy as well. PMID:37633326 LRRK2, the most common genetic cause of Parkinson’s disease, has been proposed to interact with inflammatory RIPK1 signaling through its regulation of NF-κB and microglial activation, though a direct mechanistic link remains under investigation.

The central importance of non-kinase scaffolding functions of RIPK1 must also be acknowledged. RIPK1’s death domain mediates survival signaling by recruiting cIAPs and LUBAC to complex I, independently of its kinase activity. In mouse embryos null for RIPK1, spontaneous apoptosis and necroptosis in the skin and intestine cause perinatal lethality — demonstrating that RIPK1 protein is required for survival even when kinase activity is dispensable. Therapeutic strategies must therefore inhibit RIPK1 kinase activity selectively without broadly disrupting these scaffold-dependent survival signals.

Current Therapeutic Targeting Strategies

Agent	Class	Target	Stage	Notes
DNL747	Small molecule (allosteric)	RIPK1 kinase	Phase II discontinued	CNS-penetrant; hepatotoxicity signal
DNL788	Small molecule (allosteric)	RIPK1 kinase	Phase II active	Improved hepatic safety vs DNL747
GSK2982772	Small molecule	RIPK1 kinase	Phase II (RA/IBD)	First clinical RIPK1 inhibitor
Nec-1s	Research tool	RIPK1 kinase	Preclinical	Allosteric; not CNS-optimized
Ponicidin	Natural compound	RIPK1/necroptosis	Preclinical	Demonstrated efficacy in AD models PMID:41477991

The principle that RIPK1 kinase activity is druggable without impairing NF-κB survival signaling makes this target uniquely attractive. CNS penetration is an essential requirement for neurodegeneration indications, and next-generation inhibitors are being designed with this constraint in mind.

Open Questions and Knowledge Gaps

• Whether RIPK1-dependent apoptosis or necroptosis is the dominant death mechanism in each neurodegenerative disease PMID:37633326
• The relative contributions of neuronal, astrocytic, and microglial RIPK1 to overall disease progression
• Whether RIPK1 non-kinase scaffold functions contribute to inflammatory gene expression independently of kinase activity
• Optimal biomarkers for patient stratification—pRIPK1, pMLKL, or downstream cytokine signatures
• Whether RIPK1 inhibition exerts neuroprotection primarily by blocking necroptosis or by suppressing microglial TNF production

Related Pages

• Necroptosis
• TBK1
• Neuroinflammation

References

• PMID:27493188 Ito Y et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 2016;353(6299):603-608.
• PMID:31048504 Yuan J et al. Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA 2019;116(20):9714-9722.
• PMID:30146158 Xu D et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell 2018;174(6):1477-1491.
• PMID:31745214 Rojas F et al. Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS. Cell Death Differ 2020;27(5):1628-1643.
• PMID:30815534 Dermentzaki G et al. Deletion of Ripk3 prevents motor neuron death in vitro but not in vivo. eNeuro 2019;6(1).
• PMID:34646380 Caccamo A et al. TNF-α-dependent neuronal necroptosis regulated in Alzheimer’s disease. Aging Cell 2021;20(11):e13484.
• PMID:41042431 Dong J et al. Uncovering necroptosis in Alzheimer’s disease: A systematic review. Ageing Res Rev 2025;105:102705.
• PMID:41477991 Zhang M et al. Ponicidin ameliorates Alzheimer’s disease through dual inhibition of RIPK1-mediated necroptosis. J Neuroinflammation 2026;23(1):52.
• PMID:37633326 Cao X et al. Molecular and functional characteristics of RIPK1 as a therapeutic target. Front Mol Neurosci 2023;16.